Some AstraZeneca Investors Say Talk, Others Say Walk
This article was originally published in The Pink Sheet Daily
Executive Summary
Now that only a small loophole is available to Pfizer to continue its pursuit of AstraZeneca, some shareholders in the U.K. company think it’s time for the board to talk; others are relieved a potential deal looks further from getting done.